No abstract

BackgroundRelapse is common in schizophrenia, and seriously impacts patients’ quality of life and social functioning. Many factors have been identified that may potentially increase the risk of relapse. This study was designed to investigate the relapse rate in the year following hospital discharge among Chinese patients with schizophrenia in the naturalistic condition, and to explore possible risk factors related to relapse.MethodsWe conducted a large, multicenter, retrospective, observational study in ten psychiatric hospitals throughout the People’s Republic of China. Nine hundred and ninety-two schizophrenic outpatients aged 18–65 years discharged from these hospitals between September 2011 and February 2012 with recovery/improvement of their condition were included in the study. Information about relapse and correlative factors during the year after discharge was collected by telephone interview using a questionnaire.ResultsEight hundred and seventy-six of 992 eligible patients completed the telephone survey. Of these patients, 293 (33.4%) had at least one relapse within 1 year after discharge, and 165 (18.8%) were rehospitalized. In respondents’ view, the most important factor contributing to relapse was poor medication adherence (50.7%). Approximately 30% of the respondents had a negative attitude toward medication, with the impression that there was no need to take drugs at all or for a long time. Nonadherent patients (37.9%) had a relapse rate that was 2.5-fold higher than adherent patients (54.5% versus 20.7%, P<0.001). The top five risk factors associated with relapse were nonadherence to medication (odds ratio [OR] 4.602, 95% confidence interval [CI] 3.410–6.211), being without work (OR 3.275, 95% CI 2.291–4.681), poor self-care ability (OR 2.996, 95% CI 2.129–4.214), poor interpersonal skills (OR 2.635, 95% CI 1.951–3.558), and hospitalization on more than three occasions (OR 2.299, 95% CI 1.691–3.126).ConclusionThe 1-year relapse rate after discharge in patients with schizophrenia was 33.5% in our study. The most important risk factor related to relapse was poor medication adherence, which was mainly due to patients having a negative attitude toward their medication. Lack of psychosocial support and a complicated disease history also increased the risk of relapse.

Our findings indicate that PTPRD polymorphisms might modulate AIWG.

No abstract

Background Ansofaxine (LY03005) extended-release (ER) tablet is a potential triple reuptake inhibitor of serotonin, norepinephrine, and dopamine. This study assessed the efficacy, safety, and appropriate dosage of ansofaxine for the treatment of major depressive disorder (MDD). Method A multicenter, randomized, double-blind, placebo-controlled, dose-finding, Phase 2 clinical trial was conducted in China. Eligible patients with MDD (18-65 years) were randomly assigned to receive fixed-dose ansofaxine ER tablets (40, 80, 120, or 160 mg/day) or placebo for 6 weeks. The primary outcome measure was a change in the total score on the 17-item Hamilton Depression Rating Scale (HAMD17) from baseline to week 6. Result A total of 260 patients were recruited from October 2015 to September 2017. 255 patients received the study drug as the following: 40 mg (n = 52), 80 mg (n = 52), 120 mg (n = 51), and 160 mg (n = 51) ansofaxine and placebo (n = 49). Significant differences were found in mean changes in HAMD17 total scores at week 6 in the four ansofaxine groups vs. placebo (-12.46; χ  2 = -9.71, p = 0.0447). All doses of ansofaxine were generally well-tolerated. Treatment-related adverse events (TRAEs) occurred in 141 patients (303 cases), giving TRAEs incidence rates of 51.92%, 65.38%, 56.86%, and 62.75%in the 40, 80, 120, and 160 mg ansofaxine groups and 38.78% in the placebo group. Conclusion Active doses (40, 80, 120, and 160 mg per day) of ansofaxine in a controlled setting were safe, tolerated, and effective in improving depression symptoms in MDD patients.